What's in Lee's Pharmaceutical Limited's pipeline?

Lee's Pharmaceutical Limited has 30 drugs in our index: 9 marketed, 0 filed, 8 in Phase 3, 2 in Phase 2, 11 in Phase 1.

Which companies overlap with Lee's Pharmaceutical Limited's portfolio?

Top competitors by shared drug class: Pfizer, Beijing Tiantan Hospital, GlaxoSmithKline, Odense University Hospital, University Health Network, Toronto.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lee-s-pharmaceutical-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Lee's Pharmaceutical Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lee's Pharmaceutical Limited pipeline: 9 marketed, 0 filed, 8 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9 marketed 0 filed 8 Phase 3 2 Phase 2 11 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Enantone	Enantone	marketed			Other
Zanidip	Zanidip	marketed		Voltage-gated L-type calcium channel	Cardiovascular
Clindamycin Gel	Clindamycin Gel	marketed
Iron protein succinylate oral solution	Iron protein succinylate oral solution	marketed	Iron supplement		Hematology
Lutrate	Lutrate	marketed			Other
Olmesartan medoxomil tablets	Olmesartan medoxomil tablets	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)	Cardiovascular
Aspirine	Aspirine	marketed			Other
Levocarnitine Injection	Levocarnitine Injection	marketed
Felodipine sustained-release tablet	Felodipine sustained-release tablet	marketed
Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab	Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	DNA (platinum agents), microtubules (paclitaxel), VEGF (bevacizumab)	Oncology
Lidocaine (Zingo)	Lidocaine (Zingo)	phase 3	Local anesthetic	Voltage-gated sodium channels	Anesthesia / Pain Management
intravaginal prasterone	intravaginal prasterone	phase 3	Progesterone	Progesterone receptor	Gynecology

Therapeutic area mix

Other · 4
Cardiovascular · 4
Oncology · 2
Unknown · 1
Hematology · 1
Gynecology · 1
Anesthesia / Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 2 shared drug classes
Beijing Tiantan Hospital · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Odense University Hospital · 2 shared drug classes
University Health Network, Toronto · 2 shared drug classes
Ain Shams Maternity Hospital · 2 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
Abdelwahed, Mai Mahmoud Mohamed, M.D. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lee's Pharmaceutical Limited:

Cite this brief

Drug Landscape (2026). Lee's Pharmaceutical Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lee-s-pharmaceutical-limited. Accessed 2026-05-16.